BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28974546)

  • 1. A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy.
    Luraghi P; Bigatto V; Cipriano E; Reato G; Orzan F; Sassi F; De Bacco F; Isella C; Bellomo SE; Medico E; Comoglio PM; Bertotti A; Trusolino L; Boccaccio C
    Clin Cancer Res; 2018 Feb; 24(4):807-820. PubMed ID: 28974546
    [No Abstract]   [Full Text] [Related]  

  • 2. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
    Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C
    Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
    Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
    Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 8. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
    Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
    Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
    Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
    Seguin L; Kato S; Franovic A; Camargo MF; Lesperance J; Elliott KC; Yebra M; Mielgo A; Lowy AM; Husain H; Cascone T; Diao L; Wang J; Wistuba II; Heymach JV; Lippman SM; Desgrosellier JS; Anand S; Weis SM; Cheresh DA
    Nat Cell Biol; 2014 May; 16(5):457-68. PubMed ID: 24747441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.
    De Angelis ML; Zeuner A; Policicchio E; Russo G; Bruselles A; Signore M; Vitale S; De Luca G; Pilozzi E; Boe A; Stassi G; Ricci-Vitiani L; Amoreo CA; Pagliuca A; Francescangeli F; Tartaglia M; De Maria R; Baiocchi M
    Stem Cells Transl Med; 2016 Apr; 5(4):511-23. PubMed ID: 26956206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
    Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
    Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeting of EGFR and HER2 against prostate cancer stem cells.
    Rossini A; Giussani M; Ripamonti F; Aiello P; Regondi V; Balsari A; Triulzi T; Tagliabue E
    Cancer Biol Ther; 2020 May; 21(5):463-475. PubMed ID: 32089070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.
    Bernat-Peguera A; Navarro-Ventura J; Lorenzo-Sanz L; da Silva-Diz V; Bosio M; Palomero L; Penin RM; Pérez Sidelnikova D; Bermejo JO; Taberna M; Vilariño N; Piulats JM; Mesia R; Viñals JM; González-Suárez E; Capella-Gutierrez S; Villanueva A; Viñals F; Muñoz P
    Clin Cancer Res; 2021 Mar; 27(5):1491-1504. PubMed ID: 33262138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.
    Collazo-Lorduy A; Castillo-Martin M; Wang L; Patel V; Iyer G; Jordan E; Al-Ahmadie H; Leonard I; Oh WK; Zhu J; McBride RB; Cordon-Cardo C; Solit DB; Sfakianos JP; Galsky MD
    Eur Urol; 2016 Nov; 70(5):771-775. PubMed ID: 27178450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.